Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071412
Filing Date
2025-05-14
Accepted
2025-05-14 16:15:33
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q elvn-20250331.htm   iXBRL 10-Q 2525415
2 EX-31.1 elvn-ex31_1.htm EX-31.1 16092
3 EX-31.2 elvn-ex31_2.htm EX-31.2 16077
4 EX-32.1 elvn-ex32_1.htm EX-32.1 10095
5 EX-32.2 elvn-ex32_2.htm EX-32.2 10085
6 GRAPHIC img253590672_0.jpg GRAPHIC 695121
  Complete submission text file 0000950170-25-071412.txt   10441361

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elvn-20250331.xsd EX-101.SCH 1057504
70 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20250331_htm.xml XML 1455733
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39247 | Film No.: 25945732
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)